Pluri Inc. (PLUR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PLUR
- Company Pluri Inc.
- Price $6.1
- Changes Percentage -9.7
- Change -0.655
- Day Low $6.05
- Day High $6.46
- Year High $7.13
- Year Low $3.33
- Market Cap $42,693,677
- Price Avg 50 EMA (D) $4.35
- Price Avg 200 EMA (D) $4.9
- Exchange NASDAQ
- Volume 40,414
- Average Volume 9,298
- Open $6.46
- Previous Close $6.75
- EPS -3.68
- PE -1.65
- Earnings Announcement 2025-05-07 20:00:00
- Shares Outstanding $7,010,456
Company brief: PLURI INC. (PLUR )
- Healthcare
- Biotechnology
- Mr. Yaacov Yanay
- https://pluri-biotech.com/
- IL
- N/A
- 06-30-2003
- US72942G1040
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.